Niche CNS Pipeline Privately held biopharma focused on first-in-class CNS therapies with lead candidate SXC-2023 targeting glutamatergic imbalance and oxidative stress, signaling a specialized addressable market with high unmet need.

Indication Opportunity Initial focus on impulse control disorders and trichotillomania with potential expansion to OCD and related neuropsychiatric conditions, presenting multiple entry points for potential partnerships, licensing, or co-development.

Clinical Momentum Active engagement with CNS Summit events and a history of presenting phase findings, indicating ongoing clinical validation and opportunities to connect with investigators, KOLs, and potential collaborators.

Funding and Growth Recent fundraising activity includes a substantial Series C and total funding aligned with biotech growth, suggesting readiness for partnerships, milestone-driven deals, or out-licensing discussions.

Strategic Partnerships Small company scale with experienced leadership (CMO and R&D seniors) and a focused asset portfolio positions Promentis as a potential development partner for larger pharma seeking CNS innovation and early-stage collaboration.